Literature DB >> 20981123

Genetics: How to validate a breast cancer prognostic signature.

Paul D Pharoah, Carlos Caldas.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20981123     DOI： 10.1038/nrclinonc.2010.142

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  10 in total

1.  Clinical application of the 70-gene profile: the MINDACT trial.

Authors:  Fatima Cardoso; Laura Van't Veer; Emiel Rutgers; Sherene Loi; Stella Mook; Martine J Piccart-Gebhart
Journal:  J Clin Oncol       Date:  2008-02-10       Impact factor: 44.544

2.  Gene expression profiling predicts clinical outcome of breast cancer.

Authors:  Laura J van 't Veer; Hongyue Dai; Marc J van de Vijver; Yudong D He; Augustinus A M Hart; Mao Mao; Hans L Peterse; Karin van der Kooy; Matthew J Marton; Anke T Witteveen; George J Schreiber; Ron M Kerkhoven; Chris Roberts; Peter S Linsley; René Bernards; Stephen H Friend
Journal:  Nature       Date:  2002-01-31       Impact factor: 49.962

3.  Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer.

Authors:  P M Ravdin; L A Siminoff; G J Davis; M B Mercer; J Hewlett; N Gerson; H L Parker
Journal:  J Clin Oncol       Date:  2001-02-15       Impact factor: 44.544

4.  Survival of invasive breast cancer according to the Nottingham Prognostic Index in cases diagnosed in 1990-1999.

Authors:  R W Blamey; I O Ellis; S E Pinder; A H S Lee; R D Macmillan; D A L Morgan; J F R Robertson; M J Mitchell; G R Ball; J L Haybittle; C W Elston
Journal:  Eur J Cancer       Date:  2007-02-26       Impact factor: 9.162

5.  Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies.

Authors:  Fiona M Blows; Kristy E Driver; Marjanka K Schmidt; Annegien Broeks; Flora E van Leeuwen; Jelle Wesseling; Maggie C Cheang; Karen Gelmon; Torsten O Nielsen; Carl Blomqvist; Päivi Heikkilä; Tuomas Heikkinen; Heli Nevanlinna; Lars A Akslen; Louis R Bégin; William D Foulkes; Fergus J Couch; Xianshu Wang; Vicky Cafourek; Janet E Olson; Laura Baglietto; Graham G Giles; Gianluca Severi; Catriona A McLean; Melissa C Southey; Emad Rakha; Andrew R Green; Ian O Ellis; Mark E Sherman; Jolanta Lissowska; William F Anderson; Angela Cox; Simon S Cross; Malcolm W R Reed; Elena Provenzano; Sarah-Jane Dawson; Alison M Dunning; Manjeet Humphreys; Douglas F Easton; Montserrat García-Closas; Carlos Caldas; Paul D Pharoah; David Huntsman
Journal:  PLoS Med       Date:  2010-05-25       Impact factor: 11.069

6.  The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age.

Authors:  S Mook; M K Schmidt; B Weigelt; B Kreike; I Eekhout; M J van de Vijver; A M Glas; A Floore; E J T Rutgers; L J van 't Veer
Journal:  Ann Oncol       Date:  2009-10-13       Impact factor: 32.976

7.  BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received.

Authors:  S-J Dawson; N Makretsov; F M Blows; K E Driver; E Provenzano; J Le Quesne; L Baglietto; G Severi; G G Giles; C A McLean; G Callagy; A R Green; I Ellis; K Gelmon; G Turashvili; S Leung; S Aparicio; D Huntsman; C Caldas; P Pharoah
Journal:  Br J Cancer       Date:  2010-07-27       Impact factor: 7.640

8.  PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer.

Authors:  Gordon C Wishart; Elizabeth M Azzato; David C Greenberg; Jem Rashbass; Olive Kearins; Gill Lawrence; Carlos Caldas; Paul D P Pharoah
Journal:  Breast Cancer Res       Date:  2010-01-06       Impact factor: 6.466

9.  Prevalent cases in observational studies of cancer survival: do they bias hazard ratio estimates?

Authors:  E M Azzato; D Greenberg; M Shah; F Blows; K E Driver; N E Caporaso; P D P Pharoah
Journal:  Br J Cancer       Date:  2009-04-28       Impact factor: 7.640

10.  A consensus prognostic gene expression classifier for ER positive breast cancer.

Authors:  Andrew E Teschendorff; Ali Naderi; Nuno L Barbosa-Morais; Sarah E Pinder; Ian O Ellis; Sam Aparicio; James D Brenton; Carlos Caldas
Journal:  Genome Biol       Date:  2006-10-31       Impact factor: 13.583
  10 in total
  3 in total

1.  The methyltransferase EZH2 is not required for mammary cancer development, although high EZH2 and low H3K27me3 correlate with poor prognosis of ER-positive breast cancers.

Authors:  Woo Kyun Bae; Kyung Hyun Yoo; Ji Shin Lee; Young Kim; Ik-Joo Chung; Min Ho Park; Jung Han Yoon; Priscilla A Furth; Lothar Hennighausen
Journal:  Mol Carcinog       Date:  2014-07-07       Impact factor: 4.784

2.  Aurora kinase A outperforms Ki67 as a prognostic marker in ER-positive breast cancer.

Authors:  H R Ali; S-J Dawson; F M Blows; E Provenzano; P D Pharoah; C Caldas
Journal:  Br J Cancer       Date:  2012-04-26       Impact factor: 7.640

3.  Cancer stem cell markers in breast cancer: pathological, clinical and prognostic significance.

Authors:  H Raza Ali; Sarah-Jane Dawson; Fiona M Blows; Elena Provenzano; Paul D Pharoah; Carlos Caldas
Journal:  Breast Cancer Res       Date:  2011-11-23       Impact factor: 6.466
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.